Published in Haematologica on January 12, 2011
From seeing to believing: labelling strategies for in vivo cell-tracking experiments. Interface Focus (2013) 1.17
Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis Model Mech (2014) 1.14
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs. Mol Cancer (2013) 0.90
Zebrafish: a new companion for translational research in oncology. Clin Cancer Res (2015) 0.89
Quantitative phenotyping-based in vivo chemical screening in a zebrafish model of leukemia stem cell xenotransplantation. PLoS One (2014) 0.86
Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells. PLoS One (2013) 0.86
SPIM-fluid: open source light-sheet based platform for high-throughput imaging. Biomed Opt Express (2015) 0.84
Animal models of leukemia: any closer to the real thing? Cancer Metastasis Rev (2013) 0.84
Myelopoiesis and myeloid leukaemogenesis in the zebrafish. Adv Hematol (2012) 0.83
The Study of Glioma by Xenotransplantation in Zebrafish Early Life Stages. J Histochem Cytochem (2015) 0.82
Zebrafish as a Model for the Study of Human Myeloid Malignancies. Biomed Res Int (2015) 0.81
Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica (2014) 0.80
Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discov Today (2012) 0.80
A novel zebrafish embryo xenotransplantation model to study primary human fibroblast motility in health and disease. Zebrafish (2012) 0.79
The Zebrafish as a Tool to Cancer Drug Discovery. Austin J Pharmacol Ther (2015) 0.78
In vivo chemical screening for modulators of hematopoiesis and hematological diseases. Adv Hematol (2012) 0.76
Zebrafish xenotransplantation as a tool for in vivo cancer study. Fam Cancer (2015) 0.76
The impact of tumor nitric oxide production on VEGFA expression and tumor growth in a zebrafish rat glioma xenograft model. PLoS One (2015) 0.75
Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model. Oncotarget (2016) 0.75
Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. Adv Exp Med Biol (2016) 0.75
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open (2016) 0.75
Danio rerio: Small Fish Making a Big Splash in Leukemia. Curr Pathobiol Rep (2014) 0.75
Zebrafish in Translational Cancer Research: Insight into Leukemia, Melanoma, Glioma and Endocrine Tumor Biology. Genes (Basel) (2017) 0.75
Evolutionary divergence of the vertebrate TNFAIP8 gene family: Applying the spotted gar orthology bridge to understand ohnolog loss in teleosts. PLoS One (2017) 0.75
A zebrafish mosaic assay to study mammalian stem cells in real time in vivo. J Mol Histol (2016) 0.75
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
In vivo drug discovery in the zebrafish. Nat Rev Drug Discov (2005) 6.56
Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell (2008) 5.09
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development (2002) 2.06
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn (2005) 1.78
Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology (2009) 1.75
Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis (2006) 1.74
Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci (2010) 1.67
Teratology of retinoids. Annu Rev Pharmacol Toxicol (1999) 1.34
High-throughput cell transplantation establishes that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood (2010) 1.34
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene (2001) 1.30
Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res (2007) 1.23
MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol (2008) 1.11
Development of a screening assay to identify teratogenic and embryotoxic chemicals using the zebrafish embryo. Reprod Toxicol (2009) 1.10
The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin Drug Metab Toxicol (2009) 1.00
Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol (2005) 0.97
A new zebrafish model for experimental leukemia therapy. Cancer Biol Ther (2010) 0.95
Zebrafish: genetic and embryological methods in a transparent vertebrate embryo. Methods Cell Biol (1997) 0.95
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene (2006) 0.94
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene (2003) 3.96
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Activation-induced cell death in T cells. Immunol Rev (2003) 2.82
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J (2013) 2.70
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res (2010) 2.60
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood (2009) 2.38
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature (2006) 2.17
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res (2010) 2.02
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol (2003) 1.96
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene (2002) 1.87
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res (2011) 1.84
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood (2012) 1.77
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene (2004) 1.67
Toll-like receptor gene family and TIR-domain adapters in Danio rerio. Mol Immunol (2004) 1.61
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res (2011) 1.61
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood (2007) 1.61
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Cytoprotective gene bi-1 is required for intrinsic protection from endoplasmic reticulum stress and ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2006) 1.60
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle (2011) 1.59
Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature (2006) 1.59
When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res (2012) 1.58
PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep (2012) 1.58
Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res (2012) 1.58
Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma (2013) 1.56
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica (2006) 1.54
Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell Cycle (2011) 1.53
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood (2009) 1.52
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma (2011) 1.52
Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood (2006) 1.48
Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration*. Crit Care Med (2014) 1.47
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res (2010) 1.46
Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun (2003) 1.42
Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res (2004) 1.42
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med (2007) 1.42
Vital functions for lethal caspases. Oncogene (2005) 1.40
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood (2010) 1.38
Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med (2005) 1.38
Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int (2008) 1.38
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood (2002) 1.37
Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem (2003) 1.36
Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol Cell Biol (2006) 1.36
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood (2011) 1.36
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2013) 1.35
Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. Autophagy (2009) 1.29
p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis. Cancer Res (2006) 1.27
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood (2013) 1.25
Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res (2006) 1.24
The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol (2008) 1.23
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21
HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J (2006) 1.21
Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal (2005) 1.20
Human defensins as cancer biomarkers and antitumour molecules. J Proteomics (2009) 1.20
Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J (2003) 1.19
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19
Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J (2008) 1.17
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther (2007) 1.17
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 1.16